The SMCL NGS Hub, in collaboration with the Cambridge Neuroscience Biomarkers Laboratory, is proud to support the sequencing component of the NULISA proteomics platform from Alamar Biosciences — a cutting-edge, NGS-based proteomic pipeline launched in February 2026 on the Cambridge Biomedical Campus. This powerful technology enables ultra-sensitive, high-throughput protein profiling, opening new possibilities for biomarker discovery and translational research.
If you are interested in incorporating this innovative approach into your project, please contact the Cambridge Neuroscience Biomarkers Laboratory directly through our collaborator Edward Needham, Cambridge University Hospitals NHS Foundation Trust, Neurosciences, at edward.needham2@nhs.net. We are delighted to support these opportunities.
For more information about Nulisa, please feel free to utilise the NULISA assets database.